BioCardia, Inc.
BioCardia, Inc. (BCDA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BCDA · as of Sep 30, 2025
Ownership Breakdown
18
Institutional Holders
▲ 2 vs Q2
$551,879
Total Inst. Value
▼ $41,328 vs Q2
5.80M
Shares Outstanding
freeFloat 71.68%
427,093
13F Shares Held
▲ 122,749 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BCDA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CM MANAGEMENT, LLC biological products, (no diagnostic substances) | 130.0K | 2.07% | 2.07% | $167.70M | Nov 13, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 96.5K | 1.54% | 1.54% | $124.48M | Nov 7, 2025 | ▲ 83.6K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 38.8K | 61.82% | 61.82% | $50.06M | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 38.7K | 61.71% | 61.71% | $49.97M | Nov 12, 2025 | ▲ 1.3K |
BROWN ADVISORY INC biological products, (no diagnostic substances) | 35.5K | 56.61% | 56.61% | $45.84M | Nov 14, 2025 | — held |
TWO SIGMA SECURITIES, LLC biological products, (no diagnostic substances) | 19.3K | 30.80% | 30.80% | $24.95M | Nov 14, 2025 | NEW |
COMMONWEALTH EQUITY SERVICES, LLC biological products, (no diagnostic substances) | 18.3K | 29.12% | 29.12% | $24.00M | Oct 22, 2025 | ▲ 200 |
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC biological products, (no diagnostic substances) | 17.0K | 27.08% | 27.08% | $22.44M | Oct 29, 2025 | NEW |
XTX TOPCO LTD biological products, (no diagnostic substances) | 16.2K | 25.77% | 25.77% | $20.87M | Nov 14, 2025 | NEW |
UBS GROUP AG biological products, (no diagnostic substances) | 10.7K | 17.11% | 17.11% | $13.85M | Nov 13, 2025 | ▲ 6.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
5
Increased
+91.7K shares5
New Positions
first time holders1
Decreased
−1 shares3
Sold Out
fully exitedNet shares change (top 50)
+91.7K
+91.7K / −1
Net new holders
+6
5 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BCDA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Altman Peter President and CEO | May 20, 2026 | Purchase | 1,500 | $0.92 | $1.4K | 293.3K | Form 4 ↗ |
Altman Peter President and CEO | May 19, 2026 | Purchase | 200 | $0.95 | $190 | 291.8K | Form 4 ↗ |
Altman Peter President and CEO | May 18, 2026 | Purchase | 5,700 | $0.92 | $5.2K | 291.6K | Form 4 ↗ |
Altman Peter President and CEO | May 15, 2026 | Purchase | 5,100 | $1.02 | $5.2K | 285.9K | Form 4 ↗ |
Altman Peter President and CEO | Apr 29, 2026 | Purchase | 5,000 | $1.11 | $5.6K | 280.8K | Form 4 ↗ |
Altman Peter President and CEO | Apr 21, 2026 | Purchase | 400 | $1.23 | $492 | 275.8K | Form 4 ↗ |
Altman Peter President and CEO | Apr 20, 2026 | Purchase | 600 | $1.23 | $738 | 275.4K | Form 4 ↗ |
Altman Peter President and CEO | Mar 25, 2026 | Purchase | 300 | $1.22 | $366 | 274.8K | Form 4 ↗ |
Altman Peter President and CEO | Mar 24, 2026 | Purchase | 600 | $1.24 | $744 | 274.5K | Form 4 ↗ |
Altman Peter President and CEO | Feb 4, 2026 | Purchase | 5,000 | $1.13 | $5.6K | 273.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BioCardia, Inc. (BCDA) is primarily owned by institutional investors, who hold approximately 7.4% of total shares outstanding. Company insiders own approximately 28.32%, while retail and public investors account for the remaining 64.32%.
The largest institutional shareholder of BioCardia, Inc. is CM MANAGEMENT, LLC, holding approximately 130,000 shares — equal to 2.07% of outstanding shares — as of September 30, 2025.
A total of 18 institutional investors currently hold BCDA stock, with a combined institutional value of approximately $551,879 as of the most recent 13F filing period.
Frequently asked questions
BCDA ownershipBioCardia, Inc. (BCDA) is primarily owned by institutional investors, who hold approximately 7.4% of shares. The largest shareholder is CM MANAGEMENT, LLC with a 2.07% stake. Company insiders hold 28.32%. Data sourced from SEC Form 13F as of September 30, 2025.